Hub : Traits :

Reaction Time

281 significantly associated models · 80 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	48301764	51180660	1	1	1.2e-07	2.7e-08	0.06670	89	AGBL4
2	1	96492298	97978299	1	1	1.0e-09	3.0e-08	0.30000	96	PTBP2
3	1	173437024	175663031	1	1	1.0e-07	1.1e-05	0.12200	88	RABGAP1L
4	1	204991770	206329620	3	1	2.6e-08	2.0e-07	0.39700	97	PM20D1
5	2	23453834	25278723	5	1	9.4e-09	4.7e-08	0.00577	74	AC009228.1
6	2	43844833	45285952	1	1	2.4e-08	7.6e-07	0.07180	87	PREPL
7	2	55483020	57309754	1	1	6.5e-09	2.5e-09	0.01430	83	CCDC85A
8	2	70804467	72356449	1	1	1.3e-07	4.2e-08	1.00000	100	ZNF638
9	2	172619770	173193070	1	1	3.2e-08	4.8e-08	0.34600	97	MAP1D
10	2	174136944	176043097	4	1	6.7e-10	5.7e-10	0.03480	88	OLA1
11	2	200086752	202078494	3	1	1.0e-10	4.0e-12	0.00361	82	SPATS2L
12	3	46365783	47846566	1	1	2.4e-07	2.3e-07	0.04610	85	SETD2
13	5	111499732	112950045	6	1	2.7e-11	3.0e-11	0.30500	98	APC
14	5	138933151	140423473	2	1	9.2e-09	2.5e-09	0.09010	92	PFDN1
15	6	97341715	97979053	1	1	1.2e-08	2.6e-07	0.00022	49	C6orf167
16	6	108183628	109704062	1	1	9.9e-09	7.7e-12	0.00018	70	FOXO3
17	7	32669532	33220866	2	1	2.1e-07	2.2e-07	0.17900	93	KBTBD2
18	7	122978928	124733550	1	1	1.8e-08	3.1e-08	0.00142	67	RP5-921G16.1
19	9	85899677	87315117	1	1	7.7e-09	4.7e-08	0.75800	100	RMI1
20	10	12239118	13839729	1	1	1.4e-09	1.3e-06	0.01840	76	CCDC3
21	11	45945837	47953477	10	1	4.5e-11	2.1e-09	0.07460	91	ARHGAP1
22	11	63295034	64687797	4	1	7.3e-08	1.7e-07	0.51200	98	TRPT1
23	12	48605088	50199949	5	1	5.4e-11	2.4e-12	0.00457	84	CCDC65
24	12	111154626	113517494	12	1	1.9e-11	1.4e-11	0.00886	85	SH2B3
25	16	55526487	57089130	1	1	7.6e-08	2.2e-08	0.11500	92	GNAO1
26	17	43871147	45510971	8	1	5.1e-24	9.1e-20	0.80300	100	ARL17A
27	20	46840115	48410403	2	1	8.4e-08	1.4e-06	0.32700	96	ARFGEF2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	2.14	2	0	0.0	0.00	1.0e+00	RABGAP1L SPATS2L
Bipolar Disorder or Schizophrenia	2.18	3	0	0.0	0.00	1.0e+00	ARHGAP1 OLA1 SPATS2L
Depressed Affect (Nagel 2018)	2.70	5	0	0.0	-0.70	1.9e-01	AC009228.1 ARHGAP1 CCDC85A RABGAP1L SH2B3
Depression (Nagel 2018)	2.70	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Intelligence (Savage-Jansen 2018)	4.77	9	6	13.3	-0.03	9.4e-01	ARFGEF2 ARHGAP1 ARL17A CCDC65 FOXO3 PFDN1 RABGAP1L RMI1 ZNF638
Neuroticism (Nagel 2018)	2.56	4	1	2.2	-0.15	8.5e-01	ARHGAP1 ARL17A CCDC85A RABGAP1L
Schizophrenia (2018)	2.12	1	0	0.0	0.00	1.0e+00	ARHGAP1
Schizophrenia vs Biploar Disorder	2.87	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Worry (Nagel 2018)	2.96	5	0	0.0	0.60	2.8e-01	AGBL4 ARL17A CCDC85A FOXO3 RABGAP1L
Verbal and Numeric Reasoning (VNR)	4.58	7	3	6.7	0.13	7.8e-01	ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1 RABGAP1L ZNF638
Prostate Cancer	1.52	1	0	0.0	0.00	1.0e+00	PM20D1
Coronary Artery Disease (CAD)	1.43	1	0	0.0	0.00	1.0e+00	SH2B3
LDL Cholesterol	1.96	1	0	0.0	0.00	1.0e+00	SH2B3
Primary Biliary Cirrhosis	1.87	1	1	2.2	0.00	1.0e+00	SH2B3
Rheumatoid Arthritis	1.32	1	0	0.0	0.00	1.0e+00	SH2B3
Schizophrenia (2014)	2.00	2	0	0.0	0.00	1.0e+00	ARHGAP1 PTBP2
Blood Eosinophil Count	7.13	2	2	4.4	0.00	1.0e+00	RMI1 SH2B3
Blood Platelet Count	1.82	4	4	8.9	0.11	8.9e-01	ARL17A RMI1 SH2B3 TRPT1
Blood Red Count	1.64	4	2	4.4	0.22	7.8e-01	AC009228.1 ARFGEF2 SH2B3 SPATS2L
Blood White Count	5.02	7	4	8.9	0.13	7.7e-01	AC009228.1 AGBL4 C6orf167 RMI1 SETD2 SH2B3 ZNF638
Heel T-Score	2.04	8	4	8.9	0.10	8.1e-01	APC ARHGAP1 ARL17A CCDC65 RABGAP1L RMI1 SETD2 ZNF638
BMI	2.68	10	6	13.3	-0.28	4.3e-01	AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PFDN1 PM20D1 PTBP2 TRPT1
Height	2.49	13	10	22.2	0.14	6.4e-01	AC009228.1 APC ARFGEF2 ARL17A CCDC3 CCDC85A FOXO3 PM20D1 RABGAP1L RMI1 RP5-921G16.1 SH2B3 ZNF638
Waist Hip Ratio (WHR)	1.16	2	1	2.2	0.00	1.0e+00	ARL17A SETD2
Systolic Blood Pressure	3.63	7	3	6.7	0.34	4.6e-01	ARFGEF2 ARL17A FOXO3 OLA1 SH2B3 SPATS2L ZNF638
Smoking Status	2.29	3	1	2.2	0.00	1.0e+00	AGBL4 OLA1 RABGAP1L
Allergy or Eczema	1.29	1	0	0.0	0.00	1.0e+00	SH2B3
Cardiovascular Disease	2.72	4	2	4.4	0.61	3.9e-01	ARL17A C6orf167 OLA1 SH2B3
Hypothyroidism (self reported)	4.99	1	1	2.2	0.00	1.0e+00	SH2B3
Type 2 Diabetes (T2D) (2018)	1.37	1	0	0.0	0.00	1.0e+00	SH2B3
Lung FEV1/FVC ratio	1.38	3	2	4.4	0.00	1.0e+00	ARFGEF2 FOXO3 PM20D1
Lung FVC	1.63	6	2	4.4	-0.20	7.0e-01	ARFGEF2 ARL17A FOXO3 RMI1 SH2B3 SPATS2L
Neuroticism	2.82	7	0	0.0	-0.04	9.3e-01	AC009228.1 ARHGAP1 ARL17A CCDC85A MAP1D PFDN1 RABGAP1L
Chronotype (morning person)	2.10	1	1	2.2	0.00	1.0e+00	RMI1
Hair Pigment	0.23	4	3	6.7	-0.72	2.8e-01	CCDC65 FOXO3 PM20D1 SH2B3
Tanning	0.26	2	0	0.0	0.00	1.0e+00	PFDN1 SH2B3
Hand grip strength (left)	2.29	2	1	2.2	0.00	1.0e+00	PM20D1 ZNF638
Number of treatments/medications taken	2.20	2	1	2.2	0.00	1.0e+00	RABGAP1L SH2B3
Sensitivity / hurt feelings	1.52	2	0	0.0	0.00	1.0e+00	ARL17A RMI1
Frequency of depressed mood in last 2 weeks	3.07	3	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1 CCDC85A
Relative age of first facial hair	1.45	1	0	0.0	0.00	1.0e+00	FOXO3
Systolic blood pressure, automated reading	2.73	3	2	4.4	0.00	1.0e+00	ARL17A OLA1 SH2B3
Eye problems/disorders: Diabetes related eye disease	2.22	1	0	0.0	0.00	1.0e+00	KBTBD2
Angina	1.43	1	0	0.0	0.00	1.0e+00	KBTBD2
Vitamin and mineral supplements	1.79	1	0	0.0	0.00	1.0e+00	SETD2
Pack years adult smoking proportion	1.46	1	0	0.0	0.00	1.0e+00	AGBL4
Impedance of leg (right)	1.55	7	1	2.2	0.19	6.8e-01	AC009228.1 CCDC65 FOXO3 GNAO1 PFDN1 PM20D1 SPATS2L
Leg fat-free mass (left)	2.62	10	5	11.1	-0.56	9.0e-02	AGBL4 APC FOXO3 GNAO1 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Trunk fat percentage	2.38	9	2	4.4	-0.25	5.1e-01	AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 RMI1 TRPT1
Hand grip strength (right)	2.30	4	1	2.2	0.31	6.9e-01	ARFGEF2 MAP1D PM20D1 ZNF638
Townsend deprivation index at recruitment	1.15	1	0	0.0	0.00	1.0e+00	AGBL4
Current tobacco smoking	1.68	2	0	0.0	0.00	1.0e+00	AGBL4 CCDC65
Fed-up feelings	2.83	3	1	2.2	0.00	1.0e+00	AC009228.1 ARHGAP1 SH2B3
Relative age voice broke	1.22	1	0	0.0	0.00	1.0e+00	FOXO3
Taking other prescription medications	2.42	2	1	2.2	0.00	1.0e+00	RABGAP1L SH2B3
Age when periods started (menarche)	2.17	2	2	4.4	0.00	1.0e+00	CCDC65 FOXO3
Heel bone mineral density (BMD) T-score, automated (left)	1.45	1	1	2.2	0.00	1.0e+00	ARHGAP1
High blood pressure	2.52	3	1	2.2	0.00	1.0e+00	ARL17A OLA1 SH2B3
Medication: Atenolol	1.99	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Levothyroxine sodium	4.37	1	1	2.2	0.00	1.0e+00	SH2B3
Sitting height	2.78	8	6	13.3	0.37	3.7e-01	AC009228.1 APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 ZNF638
Body mass index (BMI)	2.37	8	3	6.7	-0.08	8.6e-01	AGBL4 C6orf167 FOXO3 MAP1D OLA1 PFDN1 PTBP2 TRPT1
Impedance of leg (left)	1.62	5	1	2.2	0.22	7.2e-01	AC009228.1 GNAO1 PFDN1 PM20D1 SPATS2L
Leg predicted mass (left)	2.61	10	5	11.1	-0.56	8.9e-02	AGBL4 APC FOXO3 GNAO1 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Trunk fat mass	2.64	9	4	8.9	-0.27	4.8e-01	AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 RMI1 TRPT1
Waist circumference	2.25	5	2	4.4	-0.04	9.5e-01	AGBL4 C6orf167 FOXO3 MAP1D OLA1
Past tobacco smoking	2.75	3	0	0.0	0.00	1.0e+00	OLA1 RABGAP1L SH2B3
Alcohol usually taken with meals	2.04	2	0	0.0	0.00	1.0e+00	RABGAP1L RMI1
Nervous feelings	2.40	3	0	0.0	0.00	1.0e+00	AGBL4 ARL17A CCDC85A
Frequency of tenseness / restlessness in last 2 weeks	2.41	2	0	0.0	0.00	1.0e+00	ARL17A RABGAP1L
Hearing difficulty/problems with background noise	2.47	2	0	0.0	0.00	1.0e+00	ARHGAP1 PM20D1
Forced vital capacity (FVC)	1.91	4	2	4.4	-0.29	7.1e-01	ARFGEF2 ARL17A SPATS2L ZNF638
Heel bone mineral density (BMD) T-score, automated (right)	1.28	1	1	2.2	0.00	1.0e+00	ARHGAP1
Qualifications: None of the above	2.84	4	0	0.0	0.57	4.3e-01	ARFGEF2 C6orf167 FOXO3 SPATS2L
Heart attack	1.60	1	0	0.0	0.00	1.0e+00	SH2B3
Fluid intelligence score	3.38	6	2	4.4	-0.10	8.5e-01	ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1 ZNF638
Illnesses of siblings	2.03	1	0	0.0	0.00	1.0e+00	SH2B3
Neuroticism score	2.40	4	0	0.0	-0.24	7.6e-01	ARHGAP1 ARL17A CCDC85A RABGAP1L
Weight	2.81	11	5	11.1	-0.49	1.3e-01	AGBL4 APC ARL17A FOXO3 MAP1D OLA1 PM20D1 PTBP2 SH2B3 TRPT1 ZNF638
Impedance of arm (right)	2.34	6	3	6.7	0.06	9.1e-01	ARL17A FOXO3 PFDN1 PM20D1 RMI1 SH2B3
Arm fat percentage (right)	2.34	9	2	4.4	-0.39	3.0e-01	AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Trunk fat-free mass	2.70	9	5	11.1	-0.06	8.9e-01	AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 SH2B3 ZNF638
Hip circumference	2.22	7	3	6.7	-0.58	1.8e-01	AGBL4 FOXO3 MAP1D OLA1 PTBP2 SH2B3 TRPT1
Time employed in main current job	1.80	1	0	0.0	0.00	1.0e+00	OLA1
Father's age at death	1.61	1	1	2.2	0.00	1.0e+00	SH2B3
Frequency of tiredness / lethargy in last 2 weeks	2.41	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Number of live births	1.08	1	0	0.0	0.00	1.0e+00	TRPT1
Forced expiratory volume in 1-second (FEV1)	1.81	2	2	4.4	0.00	1.0e+00	ARFGEF2 ARL17A
Happiness	1.43	1	0	0.0	0.00	1.0e+00	ARFGEF2
Qualifications: A levels/AS levels or equivalent	2.66	3	0	0.0	0.00	1.0e+00	ARFGEF2 C6orf167 SPATS2L
Prospective memory result	2.07	1	0	0.0	0.00	1.0e+00	ZNF638
Forced expiratory volume in 1-second (FEV1), Best measure	1.43	2	2	4.4	0.00	1.0e+00	ARFGEF2 ARL17A
Impedance of arm (left)	2.39	8	3	6.7	0.19	6.5e-01	AGBL4 ARL17A FOXO3 OLA1 PFDN1 RMI1 SH2B3 SPATS2L
Arm fat mass (right)	2.62	8	4	8.9	-0.34	4.1e-01	AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Trunk predicted mass	2.71	9	5	11.1	-0.07	8.7e-01	AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 SH2B3 ZNF638
Standing height	2.47	10	9	20.0	0.14	7.0e-01	AC009228.1 APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 RMI1 SH2B3 ZNF638
Tense / 'highly strung'	2.20	2	1	2.2	0.00	1.0e+00	PM20D1 RABGAP1L
Hair/balding pattern: Pattern 4	1.48	1	0	0.0	0.00	1.0e+00	ARL17A
Birth weight of first child	2.57	2	1	2.2	0.00	1.0e+00	ARFGEF2 SH2B3
Peak expiratory flow (PEF)	2.58	3	1	2.2	0.00	1.0e+00	ARL17A FOXO3 PM20D1
Pulse wave reflection index	1.87	1	0	0.0	0.00	1.0e+00	RMI1
Qualifications: O levels/GCSEs or equivalent	2.96	2	0	0.0	0.00	1.0e+00	ARFGEF2 C6orf167
Medication: Paracetamol	1.61	1	0	0.0	0.00	1.0e+00	RABGAP1L
Headache pain in last month	1.74	1	0	0.0	0.00	1.0e+00	RABGAP1L
Medication for cholesterol, blood pressure or diabetes	1.53	1	1	2.2	0.00	1.0e+00	SH2B3
Gout (self-reported)	1.44	1	0	0.0	0.00	1.0e+00	SH2B3
Hypothyroidism/myxoedema (self-reported)	4.27	1	1	2.2	0.00	1.0e+00	SH2B3
Birth weight	1.86	1	1	2.2	0.00	1.0e+00	SH2B3
High blood pressure (siblings)	1.78	1	0	0.0	0.00	1.0e+00	SH2B3
Forced vital capacity (FVC), Best measure	1.78	3	3	6.7	0.00	1.0e+00	ARFGEF2 ARL17A ZNF638
Body fat percentage	2.38	9	1	2.2	-0.40	2.9e-01	AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Leg fat percentage (right)	2.26	8	1	2.2	-0.27	5.1e-01	AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm fat-free mass (right)	2.75	8	6	13.3	-0.59	1.3e-01	AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Comparative body size at age 10	2.18	4	2	4.4	0.08	9.2e-01	ARL17A CCDC65 MAP1D PM20D1
Worry too long after embarrassment	1.98	1	1	2.2	0.00	1.0e+00	PFDN1
Seen a psychiatrist for nerves, anxiety, tension or depression	2.13	1	0	0.0	0.00	1.0e+00	PM20D1
Qualifications: College or University degree	2.72	7	2	4.4	-0.23	6.2e-01	ARFGEF2 C6orf167 FOXO3 MAP1D PFDN1 RABGAP1L SPATS2L
Medication for pain relief, constipation, heartburn	1.94	1	1	2.2	0.00	1.0e+00	RABGAP1L
Medication: Blood pressure	2.04	1	1	2.2	0.00	1.0e+00	SH2B3
Angina (self-reported)	1.27	1	0	0.0	0.00	1.0e+00	KBTBD2
Medication: Allopurinol	1.44	1	0	0.0	0.00	1.0e+00	SH2B3
Medication: Seretide 50 evohaler	1.60	1	0	0.0	0.00	1.0e+00	AC009228.1
Mean time to correctly identify matches	17.62	27	17	37.8	0.99	2.2e-25	AC009228.1 AGBL4 APC ARFGEF2 ARHGAP1 ARL17A C6orf167 CCDC3 CCDC65 CCDC85A FOXO3 GNAO1 KBTBD2 MAP1D OLA1 PFDN1 PM20D1 PREPL PTBP2 RABGAP1L RMI1 RP5-921G16.1 SETD2 SH2B3 SPATS2L TRPT1 ZNF638
Whole body fat mass	2.65	8	3	6.7	-0.34	4.0e-01	AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Leg fat mass (right)	2.69	7	4	8.9	-0.18	7.0e-01	AGBL4 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm predicted mass (right)	2.77	9	6	13.3	-0.34	3.7e-01	AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Pulse rate, automated reading	2.37	5	1	2.2	-0.97	5.9e-03	CCDC65 PM20D1 RABGAP1L SPATS2L TRPT1
Alcohol intake frequency.	1.10	1	0	0.0	0.00	1.0e+00	AC009228.1
Comparative height size at age 10	2.67	9	6	13.3	0.03	9.5e-01	APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 RMI1 SH2B3 ZNF638
Suffer from 'nerves'	2.71	1	0	0.0	0.00	1.0e+00	ARHGAP1
Overall health rating	1.37	2	0	0.0	0.00	1.0e+00	KBTBD2 SPATS2L
Chest pain or discomfort	1.51	1	0	0.0	0.00	1.0e+00	APC
Family relationship satisfaction	1.29	1	0	0.0	0.00	1.0e+00	ARFGEF2
Medication: Aspirin	1.34	1	0	0.0	0.00	1.0e+00	SH2B3
Supplements: Vitamin C	1.59	1	0	0.0	0.00	1.0e+00	RMI1
Knee pain experienced in last month	1.54	1	0	0.0	0.00	1.0e+00	RABGAP1L
Hypertension (Self-reported)	2.35	3	1	2.2	0.00	1.0e+00	ARL17A OLA1 SH2B3
Illnesses of father: Heart disease	1.60	1	0	0.0	0.00	1.0e+00	SH2B3
Smoking status: Previous	2.91	3	0	0.0	0.00	1.0e+00	PREPL RABGAP1L SH2B3
Forced expiratory volume in 1-second (FEV1), predicted	1.65	1	0	0.0	0.00	1.0e+00	ZNF638
Whole body fat-free mass	2.73	10	5	11.1	-0.16	6.6e-01	AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Leg fat-free mass (right)	2.56	9	5	11.1	-0.41	2.7e-01	AC009228.1 AGBL4 FOXO3 GNAO1 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Arm fat percentage (left)	2.18	9	1	2.2	-0.38	3.1e-01	AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Handedness (chirality/laterality): Left-handed	1.91	1	1	2.2	0.00	1.0e+00	ARL17A
Loneliness, isolation	2.72	3	1	2.2	0.00	1.0e+00	ARFGEF2 ARHGAP1 SH2B3
Mouth/teeth dental problems: Mouth ulcers	1.08	1	0	0.0	0.00	1.0e+00	SH2B3
Medication for cholesterol	1.82	1	1	2.2	0.00	1.0e+00	SH2B3
Illnesses of father: None of the above (group 1)	2.06	2	0	0.0	0.00	1.0e+00	PM20D1 SH2B3
Smoking status: Current	1.72	2	0	0.0	0.00	1.0e+00	AGBL4 CCDC65
Whole body water mass	2.71	10	5	11.1	-0.16	6.6e-01	AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Leg predicted mass (right)	2.55	9	5	11.1	-0.41	2.8e-01	AC009228.1 AGBL4 FOXO3 GNAO1 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Arm fat mass (left)	2.60	9	4	8.9	-0.37	3.2e-01	AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PM20D1 PTBP2 TRPT1
Number of self-reported non-cancer illnesses	2.48	2	1	2.2	0.00	1.0e+00	OLA1 SH2B3
Miserableness	2.62	2	0	0.0	0.00	1.0e+00	AC009228.1 RABGAP1L
Guilty feelings	2.01	2	0	0.0	0.00	1.0e+00	AC009228.1 PFDN1
Medication: Blood pressure	2.11	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Bendroflumethiazide	1.98	1	0	0.0	0.00	1.0e+00	SH2B3
Medication: Paracetamol	1.57	1	0	0.0	0.00	1.0e+00	RABGAP1L
Medication: Lisinopril	1.69	1	0	0.0	0.00	1.0e+00	SH2B3
Illnesses of father: High blood pressure	1.79	1	0	0.0	0.00	1.0e+00	SH2B3
Ever smoked	2.03	1	0	0.0	0.00	1.0e+00	SH2B3
Basal metabolic rate	2.82	9	6	13.3	-0.55	1.3e-01	AGBL4 APC FOXO3 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Leg fat percentage (left)	2.09	8	1	2.2	-0.30	4.8e-01	AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm fat-free mass (left)	2.90	8	6	13.3	-0.58	1.3e-01	AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Diastolic blood pressure, automated reading	3.67	5	1	2.2	0.59	2.9e-01	C6orf167 GNAO1 MAP1D OLA1 SH2B3
Ever depressed for a whole week	1.35	1	0	0.0	0.00	1.0e+00	ARFGEF2
Vascular/heart problems diagnosed by doctor	2.63	3	1	2.2	0.00	1.0e+00	OLA1 SH2B3 SPATS2L
Pain experienced in last month	1.92	2	0	0.0	0.00	1.0e+00	RABGAP1L SH2B3
Heart attack/myocardial infarction (self-reported)	1.66	1	0	0.0	0.00	1.0e+00	SH2B3
Pack years of smoking	1.41	1	0	0.0	0.00	1.0e+00	AGBL4
Impedance of whole body	2.10	8	4	8.9	0.15	7.3e-01	ARL17A FOXO3 GNAO1 OLA1 PFDN1 PM20D1 RMI1 SPATS2L
Leg fat mass (left)	2.64	7	3	6.7	-0.19	6.9e-01	AGBL4 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm predicted mass (left)	2.83	8	6	13.3	-0.58	1.3e-01	AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	7	0.200	1.9
GTEx	Adipose Visceral Omentum	4	0.196	2.0
GTEx	Adrenal Gland	5	0.343	2.1
GTEx	Artery Aorta	8	0.268	2.0
GTEx	Artery Coronary	2	0.169	2.0
GTEx	Artery Tibial	8	0.213	2.0
GTEx	Brain Caudate basal ganglia	1	0.108	1.9
GTEx	Brain Cerebellar Hemisphere	2	0.134	2.0
GTEx	Brain Cerebellum	3	0.151	2.0
GTEx	Brain Cortex	3	0.290	2.0
GTEx	Brain Frontal Cortex BA9	3	0.324	2.1
GTEx	Brain Hippocampus	1	0.190	2.0
GTEx	Brain Hypothalamus	1	0.169	1.9
GTEx	Brain Nucleus accumbens basal ganglia	4	0.462	2.1
GTEx	Brain Putamen basal ganglia	1	0.160	2.0
GTEx	Breast Mammary Tissue	4	0.202	2.0
GTEx	Breast Mammary Tissue (Male)	2	0.168	1.9
GTEx	Breast Mammary Tissue (Female)	3	0.182	2.0
GTEx	Cells EBV-transformed lymphocytes	2	0.141	1.9
GTEx	Cells Transformed fibroblasts	7	0.167	1.9
GTEx	Colon Sigmoid	3	0.205	2.0
GTEx	Colon Transverse	7	0.339	2.1
GTEx	Esophagus Gastroesophageal Junction	6	0.415	2.1
GTEx	Esophagus Mucosa	7	0.211	2.0
GTEx	Esophagus Muscularis	9	0.278	2.1
GTEx	Heart Atrial Appendage	2	0.127	2.0
GTEx	Heart Left Ventricle	2	0.130	2.1
GTEx	Liver	5	0.696	2.3
GTEx	Lung	5	0.174	2.0
GTEx	Muscle Skeletal	8	0.277	2.1
GTEx	Nerve Tibial	8	0.185	2.0
GTEx	Ovary	3	0.330	2.0
GTEx	Pancreas	3	0.184	2.0
GTEx	Pituitary	7	0.627	2.2
GTEx	Prostate	2	0.240	2.0
GTEx	Skin Not Sun Exposed Suprapubic	9	0.366	2.0
GTEx	Skin Sun Exposed Lower leg	14	0.385	2.0
GTEx	Small Intestine Terminal Ileum	1	0.216	1.9
GTEx	Spleen	3	0.212	2.0
GTEx	Stomach	4	0.275	1.9
GTEx	Testis	12	0.380	2.1
GTEx	Thyroid	10	0.250	2.0
GTEx	Uterus	1	0.176	1.8
GTEx	Vagina	0	0.000	1.9
GTEx	Whole Blood	1	0.050	2.0
METSIM	Adipose	4	0.087	1.9
NTR	Blood	1	0.042	1.7
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.9
YFS	Blood	6	0.130	1.8
CommonMind	Brain Pre-frontal Cortex	9	0.167	1.9
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	5	0.113	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.097	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	5	0.116	1.8
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.9
The Cancer Genome Atlas	Lung Adenocarcinoma	3	0.102	1.8
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.119	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.125	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	1	0.060	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.8
The Cancer Genome Atlas	Prostate Adenocarcinoma	3	0.065	1.8
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.280	1.9
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.9
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.9
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	2.1